Early pregnancy biomarker discovery study for spontaneous preterm birth

(1) Objective: discover new candidate biomarkers for spontaneous preterm birth in early pregnancy samples. When fully clinically validated, early pregnancy biomarkers for sPTB give the possibility to intervene or monitor high-risk pregnancies more intensively through, as example, pelvic exams, ultrasound or sonographic cervical length surveillance.(2) Study design: Early pregnancy serum samples of eight spontaneous extreme and very preterm birth cases (<32 weeks of gestational age) without any symptoms of preeclampsia and fetal growth restriction and eight un-complicated pregnancies were analyzed by liquid chromatography mass spectrometry (LC-MS). Thirteen pro-teins, which were differentially expressed according to the LC-MS data, were subsequently selected for confirmation by enzyme-linked immunosorbent assay (ELISA).(3) Results: Differential expression of four candidate biomarkers was confirmed by ELISA with decreased early pregnancy levels of gelsolin and fibulin-1 and increased levels of c-reactive protein and complement C5 in the preterm birth group.(4) Conclusions: The confirmed candidate biomarkers are all to some extent related to inflammatory pathways and/or the complement system. This supports the hypothesis that both play a role in extreme and very preterm birth without any symptoms of preeclampsia and fetal growth restriction. The predictive value of complement C5, c-reactive protein, fibulin-1 and gelsolin should, therefore, be validated in another cohort with early preg-nancy samples.

Automated summary

Four candidate biomarkers related to inflammatory pathways and/or the complement system were confirmed through liquid chromatography mass spectrometry and enzyme-linked immunosorbent assay. These biomarkers provide the possibility to discover spontaneous preterm birth in early pregnancy and help intervene or monitor high-risk pregnancies.